Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

NRG Oncology/National Surgical Adjuvant Breast and Bowel Project Decision-Making Project-1 Results: Decision Making in Breast Cancer Risk Reduction.

Holmberg C, Bandos H, Fagerlin A, Bevers TB, Battaglia TA, Wickerham DL, McCaskill-Stevens WJ.

Cancer Prev Res (Phila). 2017 Nov;10(11):625-634. doi: 10.1158/1940-6207.CAPR-17-0076. Epub 2017 Oct 4.

PMID:
28978566
2.

Charting the Future of Cancer Health Disparities Research: A Position Statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.

Polite BN, Adams-Campbell LL, Brawley OW, Bickell N, Carethers JM, Flowers CR, Foti M, Gomez SL, Griggs JJ, Lathan CS, Li CI, Lichtenfeld JL, McCaskill-Stevens W, Paskett ED.

Cancer Res. 2017 Sep 1;77(17):4548-4555. doi: 10.1158/0008-5472.CAN-17-0623. Epub 2017 Jul 24. No abstract available.

PMID:
28739629
3.

Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.

Polite BN, Adams-Campbell LL, Brawley OW, Bickell N, Carethers JM, Flowers CR, Foti M, Gomez SL, Griggs JJ, Lathan CS, Li CI, Lichtenfeld JL, McCaskill-Stevens W, Paskett ED.

CA Cancer J Clin. 2017 Sep;67(5):353-361. doi: 10.3322/caac.21404. Epub 2017 Jul 24. No abstract available.

4.

Charting the Future of Cancer Health Disparities Research: A Position Statement From the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute.

Polite BN, Adams-Campbell LL, Brawley OW, Bickell N, Carethers JM, Flowers CR, Foti M, Gomez SL, Griggs JJ, Lathan CS, Li CI, Lichtenfeld JL, McCaskill-Stevens W, Paskett ED.

J Clin Oncol. 2017 Sep 10;35(26):3075-3082. doi: 10.1200/JCO.2017.73.6546. Epub 2017 Jul 24. No abstract available.

PMID:
28737975
5.

Deciding on breast cancer risk reduction: The role of counseling in individual decision-making - A qualitative study.

Blakeslee SB, McCaskill-Stevens W, Parker PA, Gunn CM, Bandos H, Bevers TB, Battaglia TA, Fagerlin A, Müller-Nordhorn J, Holmberg C.

Patient Educ Couns. 2017 Dec;100(12):2346-2354. doi: 10.1016/j.pec.2017.06.033. Epub 2017 Jun 27.

PMID:
28734560
6.

Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank.

McCaskill-Stevens W, Pearson DC, Kramer BS, Ford LG, Lippman SM.

Cancer Prev Res (Phila). 2017 Feb;10(2):99-107. doi: 10.1158/1940-6207.CAPR-16-0230. Epub 2016 Dec 13. Review.

7.

A Report of the Women's Health Congress Workshop on The Health of Women of Color: A Critical Intersection at the Corner of Sex/Gender and Race/Ethnicity.

Plank-Bazinet JL, Kornstein SG, Clayton JA, McCaskill-Stevens W, Wood L, Cook N, Tajuddin SM, Brown GM, Harris T, Evans MK, Begg L, Brooks CE, Miller LR, Mistretta AC, Cornelison TL.

J Womens Health (Larchmt). 2016 Jan;25(1):4-10. doi: 10.1089/jwh.2015.5666.

8.

Clinical Trial Assessment of Infrastructure Matrix Tool to Improve the Quality of Research Conduct in the Community.

Dimond EP, Zon RT, Weiner BJ, St Germain D, Denicoff AM, Dempsey K, Carrigan AC, Teal RW, Good MJ, McCaskill-Stevens W, Grubbs SS, Dimond EP, Zon RT, Weiner BJ, St Germain D, Denicoff AM, Dempsey K, Carrigan AC, Teal RW, Good MJ, McCaskill-Stevens W, Grubbs SS.

J Oncol Pract. 2016 Jan;12(1):63-4, e23-35. doi: 10.1200/JOP.2015.005181. Epub 2015 Dec 1.

9.

Increasing Minority Enrollment Onto Clinical Trials: Practical Strategies and Challenges Emerge From the NRG Oncology Accrual Workshop.

Brooks SE, Muller CY, Robinson W, Walker EM, Yeager K, Cook ED, Friedman S, Somkin CP, Brown CL, McCaskill-Stevens W.

J Oncol Pract. 2015 Nov;11(6):486-90. doi: 10.1200/JOP.2015.005934. Epub 2015 Oct 13.

10.

Cooperative Group Trials in the Community Setting.

Lloyd Wade J 3rd, Petrelli NJ, McCaskill-Stevens W.

Semin Oncol. 2015 Oct;42(5):686-92. doi: 10.1053/j.seminoncol.2015.07.011. Epub 2015 Jul 10. Review.

11.

Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement.

Ligibel JA, Alfano CM, Hershman D, Ballard RM, Bruinooge SS, Courneya KS, Daniels EC, Demark-Wahnefried W, Frank ES, Goodwin PJ, Irwin ML, Levit LA, McCaskill-Stevens W, Minasian LM, O'Rourke MA, Pierce JP, Stein KD, Thomson CA, Hudis CA.

J Clin Oncol. 2015 Nov 20;33(33):3961-7. doi: 10.1200/JCO.2015.63.1440. Epub 2015 Aug 31. Review.

12.

Gaining control over breast cancer risk: Transforming vulnerability, uncertainty, and the future through clinical trial participation - a qualitative study.

Holmberg C, Whitehouse K, Daly M, McCaskill-Stevens W.

Sociol Health Illn. 2015 Nov;37(8):1373-87. doi: 10.1111/1467-9566.12307. Epub 2015 Aug 3.

13.

Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community Oncology.

Kent EE, Mitchell SA, Castro KM, DeWalt DA, Kaluzny AD, Hautala JA, Grad O, Ballard RM, McCaskill-Stevens WJ, Kramer BS, Clauser SB.

J Clin Oncol. 2015 Aug 20;33(24):2705-11. doi: 10.1200/JCO.2014.60.6210. Epub 2015 Jul 20.

14.

My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).

Holmberg C, Waters EA, Whitehouse K, Daly M, McCaskill-Stevens W.

Med Decis Making. 2015 Nov;35(8):1010-22. doi: 10.1177/0272989X15594382. Epub 2015 Jul 16.

15.

Creating a "culture of research" in a community hospital: Strategies and tools from the National Cancer Institute Community Cancer Centers Program.

Dimond EP, St Germain D, Nacpil LM, Zaren HA, Swanson SM, Minnick C, Carrigan A, Denicoff AM, Igo KE, Acoba JD, Gonzalez MM, McCaskill-Stevens W.

Clin Trials. 2015 Jun;12(3):246-56. doi: 10.1177/1740774515571141. Epub 2015 Feb 17.

16.

Use of the National Cancer Institute Community Cancer Centers Program screening and accrual log to address cancer clinical trial accrual.

St Germain D, Denicoff AM, Dimond EP, Carrigan A, Enos RA, Gonzalez MM, Wilkinson K, Mathiason MA, Duggan B, Einolf S, McCaskill-Stevens W, Bryant DM, Thompson MA, Grubbs SS, Go RS.

J Oncol Pract. 2014 Mar;10(2):e73-80. doi: 10.1200/JOP.2013.001194. Epub 2014 Jan 14.

17.

Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute's Community Cancer Centers Program.

Langford AT, Resnicow K, Dimond EP, Denicoff AM, Germain DS, McCaskill-Stevens W, Enos RA, Carrigan A, Wilkinson K, Go RS.

Cancer. 2014 Mar 15;120(6):877-84. doi: 10.1002/cncr.28483. Epub 2013 Dec 10.

18.

Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

Siziopikou KP, Anderson SJ, Cobleigh MA, Julian TB, Arthur DW, Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Eakle JF, Leasure NC, Atkins JN, Polikoff JA, Seay TE, McCaskill-Stevens WJ, Rabinovitch R, Costantino JP, Wolmark N.

Breast Cancer Res Treat. 2013 Nov;142(2):415-21. doi: 10.1007/s10549-013-2755-z. Epub 2013 Nov 8.

19.

The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations.

Denicoff AM, McCaskill-Stevens W, Grubbs SS, Bruinooge SS, Comis RL, Devine P, Dilts DM, Duff ME, Ford JG, Joffe S, Schapira L, Weinfurt KP, Michaels M, Raghavan D, Richmond ES, Zon R, Albrecht TL, Bookman MA, Dowlati A, Enos RA, Fouad MN, Good M, Hicks WJ, Loehrer PJ Sr, Lyss AP, Wolff SN, Wujcik DM, Meropol NJ.

J Oncol Pract. 2013 Nov;9(6):267-76. doi: 10.1200/JOP.2013.001119. Epub 2013 Oct 15.

20.

Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.

Karp DD, Lee SJ, Keller SM, Wright GS, Aisner S, Belinsky SA, Johnson DH, Johnston MR, Goodman G, Clamon G, Okawara G, Marks R, Frechette E, McCaskill-Stevens W, Lippman SM, Ruckdeschel J, Khuri FR.

J Clin Oncol. 2013 Nov 20;31(33):4179-87. doi: 10.1200/JCO.2013.49.2173. Epub 2013 Sep 3.

21.

The NCI Community Oncology Research Program: what every clinician needs to know.

McCaskill-Stevens W, Lyss AP, Good M, Marsland T, Lilenbaum R.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e84. Review.

22.

National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.

McCaskill-Stevens W, Wilson JW, Cook ED, Edwards CL, Gibson RV, McElwain DL, Figueroa-Moseley CD, Paskett ED, Roberson NL, Wickerham DL, Wolmark N.

Clin Trials. 2013 Apr;10(2):280-91. doi: 10.1177/1740774512470315. Epub 2013 Jan 18.

23.

Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer.

Fisch MJ, Lee JW, Weiss M, Wagner LI, Chang VT, Cella D, Manola JB, Minasian LM, McCaskill-Stevens W, Mendoza TR, Cleeland CS.

J Clin Oncol. 2012 Jun 1;30(16):1980-8. doi: 10.1200/JCO.2011.39.2381. Epub 2012 Apr 16.

24.

Challenges in ductal carcinoma in situ risk communication and decision-making: report from an American Cancer Society and National Cancer Institute workshop.

Partridge AH, Elmore JG, Saslow D, McCaskill-Stevens W, Schnitt SJ.

CA Cancer J Clin. 2012 May-Jun;62(3):203-10. doi: 10.3322/caac.21140. Epub 2012 Apr 4.

25.

Race and the prognostic influence of p53 in women with breast cancer.

Dookeran KA, Dignam JJ, Holloway N, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S.

Ann Surg Oncol. 2012 Jul;19(7):2334-44. doi: 10.1245/s10434-011-1934-6. Epub 2012 Mar 21.

26.

A critical review of the enrollment of black patients in cancer clinical trials.

Banda DR, Germain DS, McCaskill-Stevens W, Ford JG, Swain SM.

Am Soc Clin Oncol Educ Book. 2012:153-7. doi: 10.14694/EdBook_AM.2012.32.153.

27.

Chemoprevention for breast cancer: overcoming barriers to treatment.

Brewster AM, Davidson NE, McCaskill-Stevens W.

Am Soc Clin Oncol Educ Book. 2012:85-90. doi: 10.14694/EdBook_AM.2012.32.85.

28.

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S.

J Clin Oncol. 2011 Nov 1;29(31):4160-7. doi: 10.1200/JCO.2010.32.9615. Epub 2011 Sep 26.

29.

Chemoprevention for breast cancer.

Bozovic-Spasojevic I, Azambuja E, McCaskill-Stevens W, Dinh P, Cardoso F.

Cancer Treat Rev. 2012 Aug;38(5):329-39. doi: 10.1016/j.ctrv.2011.07.005. Review.

PMID:
21856081
30.

SI RLTD: Risk Scores and Decision Making: The Anatomy of a Decision to Reduce Breast Cancer Risk.

Holmberg C, Daly M, McCaskill-Stevens W.

J Nurs Healthc Chronic Illn. 2010 Dec;2(4):271-280.

31.

Comorbidities in the aging breast cancer population: are current assessments leading to improved outcomes?

McCaskill-Stevens W, Abrams JS.

J Natl Cancer Inst. 2011 Jul 20;103(14):1072-3. doi: 10.1093/jnci/djr239. Epub 2011 Jun 30. No abstract available.

32.

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG, Anderson GL, McCaskill-Stevens W.

J Clin Oncol. 2011 Jun 10;29(17):2327-33. doi: 10.1200/JCO.2010.33.0258. Epub 2011 May 2. Erratum in: J Clin Oncol. 2013 Nov 10;31(32):4167.

33.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N.

J Natl Cancer Inst Monogr. 2010;2010(41):181-6. doi: 10.1093/jncimonographs/lgq041. Review.

34.

National Institutes of Health State-of-the-Science Conference on the Management and Diagnosis of Ductal Carcinoma in Situ: a call to action.

McCaskill-Stevens W.

J Natl Cancer Inst Monogr. 2010;2010(41):111-2. doi: 10.1093/jncimonographs/lgq033. No abstract available.

35.

Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program.

Minasian LM, Carpenter WR, Weiner BJ, Anderson DE, McCaskill-Stevens W, Nelson S, Whitman C, Kelaghan J, O'Mara AM, Kaluzny AD.

Cancer. 2010 Oct 1;116(19):4440-9. doi: 10.1002/cncr.25248. Review.

36.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.

37.

Multidisciplinary meeting on male breast cancer: summary and research recommendations.

Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F.

J Clin Oncol. 2010 Apr 20;28(12):2114-22. doi: 10.1200/JCO.2009.25.5729. Epub 2010 Mar 22.

38.

Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial.

Cook ED, Arnold KB, Hermos JA, McCaskill-Stevens W, Moody-Thomas S, Probstfield JL, Hamilton SJ, Campbell RD, Anderson KB, Minasian LM.

Clin Trials. 2010 Feb;7(1):90-9. doi: 10.1177/1740774509357227.

39.

p53 as a marker of prognosis in African-American women with breast cancer.

Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S.

Ann Surg Oncol. 2010 May;17(5):1398-405. doi: 10.1245/s10434-009-0889-3. Epub 2010 Jan 5.

PMID:
20049641
40.

Breast cancer risk assessments comparing Gail and CARE models in African-American women.

Adams-Campbell LL, Makambi KH, Frederick WA, Gaskins M, Dewitty RL, McCaskill-Stevens W.

Breast J. 2009 Sep-Oct;15 Suppl 1:S72-5. doi: 10.1111/j.1524-4741.2009.00824.x.

41.

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial.

de Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JP, Vicente M, Giuliani R, Nordenskjöld B, Gutiérez J, Andersson M, Vila MM, Jakesz R, Demol J, Dewar J, Santoro A, Lluch A, Olsen S, Gelber RD, Di Leo A, Piccart-Gebhart M.

Breast Cancer Res Treat. 2010 Jan;119(1):145-53. doi: 10.1007/s10549-009-0512-0.

PMID:
19731015
42.

Learning from experience.

Trimble EL, McCaskill-Stevens W, Denicoff A, Minig L, Minasian LM.

Oncologist. 2009 May;14(5):476-7. doi: 10.1634/theoncologist.2009-0073. Epub 2009 May 5. No abstract available.

43.

Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.

Dowsett M, Procter M, McCaskill-Stevens W, de Azambuja E, Dafni U, Rueschoff J, Jordan B, Dolci S, Abramovitz M, Stoss O, Viale G, Gelber RD, Piccart-Gebhart M, Leyland-Jones B.

J Clin Oncol. 2009 Jun 20;27(18):2962-9. doi: 10.1200/JCO.2008.19.7939. Epub 2009 Apr 13.

44.

Projecting individualized absolute invasive breast cancer risk in African American women.

Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, Anderson GL, Malone KE, Marchbanks PA, McCaskill-Stevens W, Norman SA, Simon MS, Spirtas R, Ursin G, Bernstein L.

J Natl Cancer Inst. 2007 Dec 5;99(23):1782-92. Epub 2007 Nov 27. Erratum in: J Natl Cancer Inst. 2008 Aug 6;100(15):1118. J Natl Cancer Inst. 2008 Mar 5;100(5):373.

PMID:
18042936
45.

Challenges and recommendations for advancing the state-of-the-science of quality of life assessment in symptom management trials.

Buchanan DR, O'Mara AM, Kelaghan JW, Sgambati M, McCaskill-Stevens W, Minasian L.

Cancer. 2007 Oct 1;110(7):1621-8.

46.

Addressing the soy and breast cancer relationship: review, commentary, and workshop proceedings.

Messina M, McCaskill-Stevens W, Lampe JW.

J Natl Cancer Inst. 2006 Sep 20;98(18):1275-84. Review.

PMID:
16985246
47.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP).

JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.

PMID:
16754727
48.

Barriers to racial/ethnic minority application and competition for NIH research funding.

Shavers VL, Fagan P, Lawrence D, McCaskill-Stevens W, McDonald P, Browne D, McLinden D, Christian M, Trimble E.

J Natl Med Assoc. 2005 Aug;97(8):1063-77.

49.

Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience.

McCaskill-Stevens W, McKinney MM, Whitman CG, Minasian LM.

J Clin Oncol. 2005 Aug 1;23(22):5247-54.

PMID:
16051967
50.

Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.

McCaskill-Stevens W, Wilson J, Bryant J, Mamounas E, Garvey L, James J, Cronin W, Wickerham DL.

J Natl Cancer Inst. 2004 Dec 1;96(23):1762-9. Erratum in: J Natl Cancer Inst. 2005 Jan 5;97(1):71.

PMID:
15572758

Supplemental Content

Loading ...
Support Center